Compare MIRM & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | PGNY |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 2.1B |
| IPO Year | 2019 | 2019 |
| Metric | MIRM | PGNY |
|---|---|---|
| Price | $65.07 | $26.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $87.55 | $27.44 |
| AVG Volume (30 Days) | 545.4K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2.96 |
| EPS | N/A | ★ 0.62 |
| Revenue | $471,794,000.00 | ★ $1,268,689,000.00 |
| Revenue This Year | $53.78 | $11.55 |
| Revenue Next Year | $19.91 | $9.52 |
| P/E Ratio | ★ N/A | $43.16 |
| Revenue Growth | ★ 53.66 | 11.41 |
| 52 Week Low | $36.88 | $13.86 |
| 52 Week High | $78.55 | $27.51 |
| Indicator | MIRM | PGNY |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 65.74 |
| Support Level | $63.66 | $23.78 |
| Resistance Level | $66.77 | $25.27 |
| Average True Range (ATR) | 2.99 | 0.86 |
| MACD | -0.66 | -0.09 |
| Stochastic Oscillator | 13.68 | 76.86 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.